報價延遲最少15分鐘:2025/06/28 13:08 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.9178 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-35.17/-3.24
|
|
企業價值
5.55M
|
| 資產負債 |
|
每股賬面淨值
-12.58
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
56.38K
|
|
每股收益
0.37
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/28 13:08 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The company's segments include: The Clinics Services operating segment consisting of financial information for WFI and the Atlanta Clinic; The INVOcell Device operating segment consisting of financial information relating to the manufacture and sales of the INVOcell; and The Therapeuticssegment consisting of financial information relating to acquired subsidiary, NTI. |